MERCK KGAA BUYS DANISH BIOTECH CO SURVAC FOR 11 MLN EUR TO BOOST PIPELINE

Merck KGaA said it has acquired the Danish biotechnology company Survac ApS for 11 mln eur, in a move to gain access to new technologies for cancer treatment for its drugs pipeline. The acquisition should be completed this year. Merck said Survac has developed a technology to identify and modify peptides that are useful for therapeutic cancer vaccines.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/11/18/afx2345687.html)